Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Thomas Website

Craig J. Thomas, Ph.D.

Selected Publications
1)  Lin DC, Xu L, Ding LW, Sharma A, Liu LZ, Yang H, Tan P, Vadgama J, Karlan BY, Lester J, Urban N, Schummer M, Doan N, Said JW, Sun H, Walsh M, Thomas CJ, Patel P, Yin D, Chan D, Koeffler HP.
Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers.
Proc. Natl. Acad. Sci. U.S.A. 110: 6109-14, 2013. [Journal]
2)  Duveau DY, Hu X, Walsh MJ, Shukla S, Skoumbourdis AP, Boxer MB, Ambudkar SV, Shen M, Thomas CJ.
Synthesis and biological evaluation of analogues of the kinase inhibitor nilotinib as Abl and Kit inhibitors.
Bioorg. Med. Chem. Lett. 23: 682-6, 2013. [Journal]
3)  Johnson BC, Pauly GT, Rai G, Patel D, Bauman JD, Baker HL, Das K, Schneider JP, Maloney DJ, Arnold E, Thomas CJ, Hughes SH.
A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants.
Retrovirology. 9: 99, 2012. [Journal]
4)  Mott BT, Cheng KC, Guha R, Kommer VP, Williams DL, Vermeire JJ, Cappello M, Maloney DJ, Rai G, Jadhav A, Simeonov A, Inglese J, Posner GH, Thomas CJ.
A furoxan-amodiaquine hybrid as a potential therapeutic for three parasitic diseases().
Medchemcomm. 3: 1505-1511, 2012. [Journal]
5)  Zhu J, Choi WS, McCoy JG, Negri A, Zhu J, Naini S, Li J, Shen M, Huang W, Bougie D, Rasmussen M, Aster R, Thomas CJ, Filizola M, Springer TA, Coller BS.
Structure-guided design of a high-affinity platelet integrin aIIbß3 receptor antagonist that disrupts Mg²? binding to the MIDAS.
Sci Transl Med. 4: 125ra32, 2012. [Journal]
6)  Nayar R, Enos M, Prince A, Shin H, Hemmers S, Jiang JK, Klein U, Thomas CJ, Berg LJ.
TCR signaling via Tec kinase ITK and interferon regulatory factor 4 (IRF4) regulates CD8+ T-cell differentiation.
Proc. Natl. Acad. Sci. U.S.A. 109: E2794-802, 2012. [Journal]
7)  Mathews LA, Keller JM, Goodwin BL, Guha R, Shinn P, Mull R, Thomas CJ, de Kluyver RL, Sayers TJ, Ferrer M.
A 1536-Well Quantitative High-Throughput Screen to Identify Compounds Targeting Cancer Stem Cells.
J. Biomol. Screen. 17: 1231-42, 2012. [Journal]
8)  Law AJ, Wang Y, Sei Y, O'Donnell P, Piantadosi P, Papaleo F, Straub RE, Huang W, Thomas CJ, Vakkalanka R, Besterman AD, Lipska BK, Hyde TM, Harrison PJ, Kleinman JE, Weinberger DR.
Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy.
Proc. Natl. Acad. Sci. U.S.A. 109: 12165-70, 2012. [Journal]
9)  Anastasiou D, Yu Y, Israelsen WJ, Jiang J, Boxer MB, Hong BS, Tempel W, Dimov S, Shen M, Jha A, Yang H, Mattaini KR, Metallo CM, Fiske BP, Courtney KD, Malstrom S, Khan TM, Kung C, Skoumbourdis AP, Veith H, Southall N, Walsh MJ, Brimacombe KR, Leister W, Lunt SY, Johnson ZR, Yen KE, Kunii K, Davidson SM, Christofk HR, Austin CP, Inglese J, Harris MH, Asara JM, Stephanopoulos G, Salituro FG, Jin S, Dang L, Auld DS, Park H, Cantley LC, Thomas CJ, Heiden MG.
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis.
Nat. Chem. Biol. 8: 839-47, 2012. [Journal]
10)  Heidebrecht RW, Mulrooney C, Austin CP, Barker RH, Beaudoin JA, Cheng KC, Comer E, Dandapani S, Dick J, Duvall JR, Ekland EH, Fidock DA, Fitzgerald ME, Foley M, Guha R, Hinkson P, Kramer M, Lukens AK, Masi D, Marcaurelle LA, Su X, Thomas CJ, Weïwer M, Wiegand RC, Wirth D, Xia M, Yuan J, Zhao J, Palmer M, Munoz B, Schreiber S.
Diversity-Oriented Synthesis Yields a Novel Lead for the Treatment of Malaria.
ACS Med. Chem. Lett. 3: 112-117, 2012. [Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 5/1/2013.